| Literature DB >> 24808954 |
Yaniv Hamzany1, Daniel Brasnu2, Thomas Shpitzer1, Jacob Shvero1.
Abstract
The growing practice of endoscopic surgery has changed the therapeutic management of selected head and neck cancers. Although a negative surgical margin in resection of neoplasm is the most important surgical principle in oncologic surgery, controversies exist regarding assessment and interpretation of the status of margin resection. The aim of this review was to summarize the literature considering the assessment and feasibility of negative margins in transoral laser microsurgery (TLM) and transoral robotic surgery (TORS). Free margin status is being approached differently in vocal cord cancer (1-2 mm) compared with other sites in the upper aerodigestive tract (2-5 mm). Exposure, orientation of the pathological specimen, and co-operation with the pathologist are crucial principles needed to be followed in transoral surgery. Piecemeal resection to better expose deep tumor involvement and biopsies taken from surgical margins surrounding site of resection can improve margin assessment. High rates of negative surgical margins can be achieved with TLM and TORS. Adjuvant treatment decision should take into consideration also the surgeon's judgment with regard to the completeness of tumor resection.Entities:
Keywords: Cancer; glottis; laser; margin; robot; transoral
Year: 2014 PMID: 24808954 PMCID: PMC4011481 DOI: 10.5041/RMMJ.10150
Source DB: PubMed Journal: Rambam Maimonides Med J ISSN: 2076-9172
Studies Addressing the Impact of Margins Status on Local Control in TLM for Glottic Cancer
| Fang | 75 | T1, T2 | NA | yes | I: 10 (10%) | none | 18% | 3% | no | 84% | |
| Michel | 64 | T1 | 1–2 mm | no | 24 (37.5%) | 10; re-resection | 10% | 17% | 5% | no | 91% |
| Peretti | 595 | Tis-T3 | >1 mm | no | 300 (50%) | 71; re-resection | 14% | 7%–15% | 6% | yes | 85% |
| Ansain | 274 | Tis-T1 | >1 mm | no | I: 40 (15%) | 28; RT | 8% | 14% | 2% | yes | 91% |
| Hartl | 79 | Tis-T1 | >2 mm | no | I: 20 (25%) | 3; resection | 0 | 24% | 9% | no | 96% |
| Manola | 31 | T1 | 1–2 mm | no | 3 (10%) | 3; resection | 0 | 3% | 0 | no | 95% |
| Brondbo | 171 | T1 | 1–2 mm | no | 62 (36%) | none | 14.5% | 4% | no | 91% | |
| Crespo | 40 | T1, T2 | NA | yes | P: 8 (20%) | 2; RT | 37.5% | 0 | yes | 93% |
I, inadequate; NA, data not available; P, Positive; RT, radiation therapy; TLM, transoral laser microsurgery.
Up-to-date Series of TORS for Upper Aerodigestive Tract Cancer with Assessment of Surgical Margins.
| Boudreaux | 2009 | Oral cavity, oropharynx, hypopharynx, supraglottic | 29 | NA | yes | 0 | NA |
| Weinstein | 2010 | Oropharynx | 47 | ≤2 mm | yes | 1 (2%) | 98% |
| White | 2010 | Oral cavity, oropharynx, supraglottic | 89 | NA | yes | 3 (3%) | 97% |
| Hurtuk | 2011 | Oropharynx, hypopharynx, larynx (1–3) | 54 | ≤2 mm | yes | 4 (7%) | 98% |
| Lawson | 2011 | Oral cavity, oropharynx, hypopharynx, supraglottic (1–3) | 24 | NA | yes | 0 | 92% |
| Hans | 2011 | Oropharynx, hypopharynx, supraglottic | 23 | NA | NA | 1 (4%) | 100% |
| Aubry | 2011 | Oropharynx, hypopharynx, supraglottic (1–3) | 17 | NA | yes | 2 (12%) | 100% |
| Genden | 2011 | Oropharynx, hypopharynx, larynx (1–3) | 30 | NA | yes | 10 (33%) | 91% |
| Park | 2012 | Hypopharyngeal | 23 | ≤5 mm | NA | 2 (9%) | 100% |
| Park | 2013 | Oropharynx | 39 | ≤5 mm | NA | 2 (5%) | 95% |
| Park | 2013 | Supraglottic (1–3) | 16 | NA | NA | 2 (12%) | 100% |
Mean follow-up time <12 months.
TORS, transoral robotic surgery; NA, data not available.